Bioinformatics Analysis of MiRNAs in the Neuroblastoma 11q-deleted Region Reveals a Role of MiR-548l in Both 11q-deleted and MYCN Amplified Tumour Cells

Overview

Journal Sci Rep

Specialty Science

Date 2022 Nov 17

PMID 36396668

Authors

Sanja Jurcevic

Simon Keane

Emmy Borgmastars

Zelmina Lubovac-Pilav

Katarina Ejeskar

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a childhood tumour that is responsible for approximately 15% of all childhood cancer deaths. Neuroblastoma tumours with amplification of the oncogene MYCN are aggressive, however, another aggressive subgroup without MYCN amplification also exists; rather, they have a deleted region at chromosome arm 11q. Twenty-six miRNAs are located within the breakpoint region of chromosome 11q and have been checked for a possible involvement in development of neuroblastoma due to the genomic alteration. Target genes of these miRNAs are involved in pathways associated with cancer, including proliferation, apoptosis and DNA repair. We could show that miR-548l found within the 11q region is downregulated in neuroblastoma cell lines with 11q deletion or MYCN amplification. In addition, we showed that the restoration of miR-548l level in a neuroblastoma cell line led to a decreased proliferation of these cells as well as a decrease in the percentage of cells in the S phase. We also found that miR-548l overexpression suppressed cell viability and promoted apoptosis, while miR-548l knockdown promoted cell viability and inhibited apoptosis in neuroblastoma cells. Our results indicate that 11q-deleted neuroblastoma and MYCN amplified neuroblastoma coalesce by downregulating miR-548l.

References

Keane S, Martinsson T, Kogner P, Ejeskar K . The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma. Cancer Cell Int. 2021; 21(1):170. PMC: 7962242. DOI: 10.1186/s12935-021-01851-w. View

Keane S, Ameen S, Lindlof A, Ejeskar K . Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival. Cell Commun Signal. 2020; 18(1):65. PMC: 7171851. DOI: 10.1186/s12964-020-00553-6. View

Misiak D, Hagemann S, Bell J, Busch B, Lederer M, Bley N . The MicroRNA Landscape of MYCN-Amplified Neuroblastoma. Front Oncol. 2021; 11:647737. PMC: 8138323. DOI: 10.3389/fonc.2021.647737. View

Rodrigo M, Buchtelova H, Jimenez A, Adam P, Babula P, Heger Z . Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells. Cells. 2019; 8(3). PMC: 6469049. DOI: 10.3390/cells8030235. View

Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R . Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene. 2007; 27(10):1478-88. DOI: 10.1038/sj.onc.1210769. View

Peng Y, Croce C . The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2017; 1:15004. PMC: 5661652. DOI: 10.1038/sigtrans.2015.4. View

Shen X, Xu X, Xie C, Liu H, Yang D, Zhang J . YAP promotes the proliferation of neuroblastoma cells through decreasing the nuclear location of p27 mediated by Akt. Cell Prolif. 2019; 53(2):e12734. PMC: 7046475. DOI: 10.1111/cpr.12734. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Upton K, Modi A, Patel K, Kendsersky N, Conkrite K, Sussman R . Epigenomic profiling of neuroblastoma cell lines. Sci Data. 2020; 7(1):116. PMC: 7156688. DOI: 10.1038/s41597-020-0458-y. View

10.

Salloum R, Garrison A, von Allmen D, Sheridan R, Towbin A, Adams D . Relapsed perinatal neuroblastoma after expectant observation. Pediatr Blood Cancer. 2014; 62(1):160-2. DOI: 10.1002/pbc.25218. View

11.

Sussman R, Rokita J, Huang K, Raman P, Rathi K, Martinez D . CAMKV Is a Candidate Immunotherapeutic Target in Amplified Neuroblastoma. Front Oncol. 2020; 10:302. PMC: 7069022. DOI: 10.3389/fonc.2020.00302. View

12.

Hill-Kayser C, Tochner Z, Li Y, Kurtz G, Lustig R, James P . Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. Int J Radiat Oncol Biol Phys. 2019; 104(2):401-408. DOI: 10.1016/j.ijrobp.2019.01.095. View

13.

Hagenbuchner J, Rupp M, Salvador C, Meister B, Kiechl-Kohlendorfer U, Muller T . Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma. Oncotarget. 2016; 7(47):77591-77606. PMC: 5363607. DOI: 10.18632/oncotarget.12728. View

14.

Chin C, Chen S, Wu H, Ho C, Ko M, Lin C . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014; 8 Suppl 4:S11. PMC: 4290687. DOI: 10.1186/1752-0509-8-S4-S11. View

15.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

16.

Lee R, Ambros V . An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862-4. DOI: 10.1126/science.1065329. View

17.

Siaw J, Javanmardi N, Van den Eynden J, Lind D, Fransson S, Martinez-Monleon A . 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma. Cell Rep. 2020; 32(12):108171. DOI: 10.1016/j.celrep.2020.108171. View

18.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

19.

Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele S . The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015; 35(8):1350-62. PMC: 4372700. DOI: 10.1128/MCB.00102-15. View

20.

Yang C, Tan J, Zhu J, Wang S, Wei G . YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma. Oncotarget. 2017; 8(23):37154-37163. PMC: 5514898. DOI: 10.18632/oncotarget.16209. View